This is a Phase 2, double-blind, randomized, placebo-controlled study to evaluate the
efficacy and safety of sotatercept versus placebo in adults with Cpc-PH due to HFpEF.
The objective of this study is to evaluate the efficacy, safety and tolerability of
sotatercept versus placebo in adults with Cpc-PH due to HFpEF. Efficacy is measured by change
from baseline in pulmonary vascular resistance (PVR, primary endpoint) and 6-minute walk
distance (6MWD, key secondary endpoint).
The objective of this study is to evaluate the effects of sotatercept (MK-7962, formerly
called ACE-011) treatment (plus maximum tolerated background pulmonary arterial hypertension
(PAH) therapy) versus placebo (plus maximum tolerated background PAH therapy) on time to
first event of all cause death, lung transplantation, or PAH worsening-related
hospitalization of ≥24 hours, in participants with World Health Organization (WHO) functional
class (FC) III or FC IV PAH at high risk of mortality.
This is a two-part (Phase 2/Phase 3) study of MK-5475, an inhaled soluble guanylate cyclase
stimulator, in participants with pulmonary arterial hypertension (PAH).
The first part (Phase 2) will assess three different doses of MK-5475 compared to placebo in
a base period of 12 weeks, followed by comparison of three different doses of MK-5475 during
an optional 24 month extension period. The treatment dose with the best efficacy and safety
profile in the phase 2 cohort base period will be selected for use in the second part (Phase
3) of the study. The primary hypothesis of Phase 2 is that at least one MK-5475 dose is
The purpose of the study is to enable participants with pulmonary hypertension (PH) currently
treated with study intervention(s) in a clinical study (parent studies [NCT03422328,
NCT03904693 and NCT04565990]), to continue to benefit from the intervention after closure of
the parent study in case they have no alternative means of access to the study intervention.
This study will allow assessment of the long-term safety of each study intervention.
A randomized, double-blind, placebo-controlled dose escalation and verification study to
assess the safety and efficacy of pulsed inhaled nitric oxide (iNO) in subjects at risk for
pulmonary hypertension associated with pulmonary fibrosis on long term oxygen therapy (Part 1
and Part 2) - REBUILD
This is a prospective, multicenter, open-label, randomized, controlled, parallel Phase 3
study with an open-label single-arm extension period to evaluate pharmacokinetics (PK),
safety and efficacy of macitentan in children with pulmonary arterial hypertension (PAH).
The purpose of the study is to evaluate the effect of macitentan 75 mg versus placebo on
exercise capacity at Week 28 in participants with chronic thromboembolic pulmonary
The main objective of the study is to assess the effect of treprostinil palmitil inhalation
powder (TPIP) compared with placebo on pulmonary vascular resistance.
This is an open-label, multicentre study evaluating the effect, safety and tolerability of
the two regio isomers 1-(nitrosooxy)propan-2-ol and 2- (nitrosooxy)propan-1-ol (PDNO)
infusion given to COVID-19 patients with acute pulmonary hypertension (aPH).
To evaluate the effect of renal insufficiency on the pharmacokinetics of TPN171H tablets
after single dose oral administration, so as to provide basis for formulating clinical
medication plan for patients with renal insufficiency; To evaluate the safety of TPN171H
tablets in patients with renal insufficiency and healthy subjects